Ibrahim Prabha N.,Bollag Gideon,Hirth Klaus-Peter,Lin Paul,West Brian
申请号:
NZ63048313
公开号:
NZ630483A
申请日:
2013.03.18
申请国别(地区):
NZ
年份:
2017
代理人:
摘要:
Disclosed is the use of Pexidartinib (5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{ [6-(trifluoromethyl)-3-pyridinyl]methyl} -2-pyridinamine) in the manufacture of a medicament for the treatment of pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumour (TGCT), plexiform neurofibromasin and in combination with sirolimus for the treatment of malignant peripheral nerve sheath tumours (MPNST). Also disclosed are methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof. The compounds used have a pyrrolo[2,3-b]pyridine core structure.